Press Release

Alembic Pharmaceuticals Limited announced it has received a US Food & Drug Administration (USFDA) Tentative Approval for its Binimetinib Tablets, 45 mg. This significant regulatory milestone indicates the company has met the necessary quality and safety standards for the drug. While "tentative," it paves the way for potential future market entry in the United States. For investors, this suggests a future expansion of Alembic's product portfolio and a new revenue opportunity once final approval is obtained and the product is launched.